In HR+ primary breast cancer, the translation rate of HER2-zero expression to HER2-low expression was much higher than the translation rate of HER2-low status to HER2-zero status, and therefore, more cases with HER2-low status emerged in HR+ breast cancer. The gene discussed is ERBB2; the disease is breast carcinoma.